1. Home
  2. CIVB vs DBVT Comparison

CIVB vs DBVT Comparison

Compare CIVB & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CIVB
  • DBVT
  • Stock Information
  • Founded
  • CIVB 1884
  • DBVT 2002
  • Country
  • CIVB United States
  • DBVT France
  • Employees
  • CIVB N/A
  • DBVT N/A
  • Industry
  • CIVB Major Banks
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CIVB Finance
  • DBVT Health Care
  • Exchange
  • CIVB Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • CIVB 402.3M
  • DBVT 464.0M
  • IPO Year
  • CIVB N/A
  • DBVT N/A
  • Fundamental
  • Price
  • CIVB $22.19
  • DBVT $15.49
  • Analyst Decision
  • CIVB Buy
  • DBVT Buy
  • Analyst Count
  • CIVB 5
  • DBVT 4
  • Target Price
  • CIVB $25.25
  • DBVT $14.81
  • AVG Volume (30 Days)
  • CIVB 117.7K
  • DBVT 194.6K
  • Earning Date
  • CIVB 10-23-2025
  • DBVT 11-10-2025
  • Dividend Yield
  • CIVB 3.07%
  • DBVT N/A
  • EPS Growth
  • CIVB 33.82
  • DBVT N/A
  • EPS
  • CIVB 2.66
  • DBVT N/A
  • Revenue
  • CIVB $163,095,000.00
  • DBVT $3,800,000.00
  • Revenue This Year
  • CIVB $17.30
  • DBVT $1,743.46
  • Revenue Next Year
  • CIVB $12.90
  • DBVT $1,044.34
  • P/E Ratio
  • CIVB $8.33
  • DBVT N/A
  • Revenue Growth
  • CIVB 11.59
  • DBVT N/A
  • 52 Week Low
  • CIVB $17.47
  • DBVT $2.21
  • 52 Week High
  • CIVB $25.59
  • DBVT $18.00
  • Technical
  • Relative Strength Index (RSI)
  • CIVB 64.13
  • DBVT 61.67
  • Support Level
  • CIVB $19.84
  • DBVT $14.85
  • Resistance Level
  • CIVB $21.64
  • DBVT $17.90
  • Average True Range (ATR)
  • CIVB 0.72
  • DBVT 1.15
  • MACD
  • CIVB 0.15
  • DBVT -0.13
  • Stochastic Oscillator
  • CIVB 90.38
  • DBVT 41.89

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: